The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033

The optimal treatment for patients with low-grade glioma (LGG) WHO grade II remains controversial. Overall survival ranges from 2 to over 15 years depending on molecular and clinical factors. Hence, risk-adjusted treatments are required for optimizing outcome and quality of life. We aim at identifyi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bady, Pierre, Kurscheid, Sebastian, Delorenzi, Mauro, Gorlia, Thierry, van den Bent, Martin J., Hoang-Xuan, Khê, Vauléon, Élodie, Gijtenbeek, Anja, Enting, Roelien, Thiessen, Brian, Chinot, Olivier, Dhermain, Frédéric, Brandes, Alba A., Reijneveld, Jaap C., Marosi, Christine, Taphoorn, Martin J. B., Wick, Wolfgang, von Deimling, Andreas, French, Pim, Stupp, Roger, Baumert, Brigitta G., Hegi, Monika E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978935/
https://www.ncbi.nlm.nih.gov/pubmed/29368212
http://dx.doi.org/10.1007/s00401-018-1810-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978935/
https://www.ncbi.nlm.nih.gov/pubmed/29368212
http://dx.doi.org/10.1007/s00401-018-1810-6

Ejemplares similares